Related Posts

• Public Announcement 12-14-2023

  HUCK MEDICAL TECHNOLOGIES, INC. - Public Announcement 12-14-2023 Tim Koehler Joins Huck Medical Technologies Director of Global Business Development Huck Medical Technologies (HMT) is pleased to announce the addition of Tim Koehler to the HMT team. Tim will be serving as the Director of Global Business Development, bringing many years of expertise to HMT. Tim has accumulated over 40 years of domestic and international business experience across multiple industries partnering with the worlds largest manufacturers, as well establishing his own manufacturing businesses. With an Engineering background, Tim brings the exceptional capacity for team bulding, business development and product penetration and positioning. Tim will lead HMT efforts to strengthen existing relationships and engage new partnershps that can benefit from the valuable experience the Huck team brings to the table. The expansion of our domestic and global footprint is one of the many objectives soon to be realized thru Tim's leadership. His commttment to advise and direct will ensure HMT and all our partnerships are focused on growth and a continued trajectory toward success. As Huck Medical Technologies continues to partner with innovators ...

• Public Announcement 06-20-19

  HUCK MEDICAL TECHNOLOGIES, INC. – Public Announcement 06-20-19 Jack Merritt Joins Huck Medical Technologies Board Of Directors Huck Medical Technologies (HMT), is pleased to announce the addition of Jack Merritt to the HMT team. Jack will be serving the as a Senior Advisor and Board Chair, bringing significant value to the organization. Jack has over 30 years of broadly based sales, marketing and general management experience in the medical device industry. His experience includes 20 years with subsidiaries of Johnson and Johnson, and significant experience with early stage companies, in both domestic and international markets. Most recently, Jack was President and Chief Executive Officer of ICON Medical Corp., an early stage company developing innovative products for interventional cardiology. Jack joined ICON in 2004 and led the company through several important stages of fundraising and product development. He successfully raised over $15 million in private funding, licensed a state-of-the-art drug and recruited internationally known clinical investigators. Jack also negotiated the out licensing of the first generation technology after achieving CE mark, providing substantial non-dilutive funding. Prior to joining ICON, Jack served as President of the ...